Mo Zhang

Mo Zhang

Auto-generated profile, based on publicly available information

Mo Zhang

Department of Urology, The First Hospital of China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
MZMo Zhang
Mo Zhang
ZCZhengjie Chen
Zhengjie Chen
WLWangmin Liu
Wangmin Liu
LLLin Lin
Lin Lin
LWLina Wu
Lina Wu
MZMo Zhang
Mo Zhang
Background: Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men worldwide, and its incidence has risen substantially in recent years. Therefore, there is an urgent need to identify novel biomarkers and precise therapeutic targets for managing PCa progression and recurrence. Methods: We investigated the clinical significance of NCAPG2 in PCa by exploring public datasets and our tissue microarray. Receiver operating characteristic (ROC) curve and survival analyses were performed to evaluate the correlation between NCAPG2 and PCa progression. Cell proliferation, wound healing, transwell, flow cytometry, cell cycle, tumor sphere formation, immunofluorescence (IF), co-immunoprecipitation (co-IP), and chromatin immunoprecipitation (ChIP) assays were conducted to further elucidate the molecular mechanism of NCAPG2 in PCa. Subcutaneous and orthotopic xenograft models were applied to investigate the effects of NCAPG2 on PCa proliferation in vivo. Tandem mass tag (TMT) quantitative proteomics was utilized to detect proteomic changes under NCAPG2 overexpression. Results: NCAPG2 was significantly upregulated in PCa, and its overexpression was associated with PCa progression and unfavorable prognosis. Knockdown of NCAPG2 inhibited the malignant behavior of PCa cells, whereas its overexpression promoted PCa aggressiveness. NCAPG2 depletion attenuated the development and growth of PCa in vivo. TMT quantitative proteomics analyses indicated that c-MYC activity was strongly correlated with NCAPG2 expression. The malignancy-promoting effect of NCAPG2 in PCa was mediated via c-MYC. NCAPG2 could directly bind to STAT3 and induce STAT3 occupancy on the MYC promoter, thus to transcriptionally activate c-MYC expression. Finally, we identified that NCAPG2 was positively correlated with cancer stem cell (CSC) markers and enhanced self-renewal capacity of PCa cells. Conclusions: NCAPG2 is highly expressed in PCa, and its level is significantly associated with PCa prognosis. NCAPG2 promotes PCa malignancy and drives cancer stemness via the STAT3/c-MYC signaling axis, highlighting its potential as a therapeutic target for PCa.

16 October 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JYJianfeng Ye
Jianfeng Ye
WLWangmin Liu
Wangmin Liu
XYXueyang Yu
Xueyang Yu
LWLina Wu
Lina Wu
ZCZhengjie Chen
Zhengjie Chen
MZMo Zhang
Mo Zhang
Homeobox A5 (HOXA5), a homeodomain transcription factor, is considered a tumor suppressor in cancer progression; however, its function in prostate cancer (PCa) remains unclear. This study focused on the relevance of HOXA5 in PCa progression. We identified the downregulation of HOXA5 in PCa tissues based on the TCGA database and further verified in 30-paired PCa and adjacent normal tissues. Functional studies revealed that HOXA5 upregulation impaired the stem-like characteristics and malignant behaviors of PCa cells in vitro and in vivo. Mechanistically, HOXA5 was found to be regulated by tumor necrosis factor receptor-associated factor 7 (TRAF7), a putative E3-ubiquitin ligase. We observed that TRAF7 was overexpressed in PCa and subsequently enhanced the degradation of HOXA5 protein via its ubiquitin ligase activity, contributing to the acquisition of an aggressive PCa phenotype. For its downstream mechanism, we demonstrated that sprouty RTK signaling antagonist 2 (SPRY2) served as a downstream target of HOXA5. HOXA5 could directly bind to the SPRY2 promoter, thereby regulating the SPRY2-mediated MEK/ERK signaling pathway. Silencing SPRY2 largely compromised the tumor-suppressive effect of HOXA5 in PCa progression and cancer stemness. Our findings highlight the previously-underappreciated signaling axis of TRAF7–HOXA5–SPRY2, which provides a novel prognostic and therapeutic target for PCa treatment.

12 May 2025 in International Journal of Surgery
Verified
Journal Article
Open access
YYYufei Mm Yu
Yufei Mm Yu
RRRobert E. Reiter
Robert E. Reiter
MZMo Zhang
Mo Zhang
Prostate cancer (PCa) is one of the most common malignancies affecting the male reproductive system. Robot-assisted radical prostatectomy (RARP) has been a standard treatment for PCa for over 20 years. However, postoperative urinary incontinence remains a frequent complication for patients who undergo RARP. Numerous surgical techniques have been developed to improve postoperative continence recovery, broadly categorized into preservation and reconstruction methods. Preservation techniques include safeguarding the bladder neck, distal urethra, detrusor apron, retropubic space, neurovascular bundles, and controlling the dorsal venous complex. Reconstruction techniques aim to mitigate the impairment of urethral sphincter function caused by surgery. While these approaches substantially enhance post-RARP urinary continence recovery, challenges remain in tailoring surgical plans to individual patient needs. This review explores the application of these representative techniques, discusses their current limitations, and highlights potential directions for future advancement.

25 July 2025 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
WLWangmin Liu
Wangmin Liu
SZSiyu Zhou
Siyu Zhou
XYXueyang Yu
Xueyang Yu
YYYufei Yu
Yufei Yu
HSHongbo Su
Hongbo Su
MZMo Zhang
Mo Zhang

1 June 2026 in Intelligent Oncology
Verified
Journal Article
Open access
BRBiao Ran
Biao Ran
SQShi Qiu
Shi Qiu
MZMo Zhang
Mo Zhang
ZCZeyu Chen
Zeyu Chen
BCBo Chen
Bo Chen
QWQiang Wei
Qiang Wei